Clearmind Doses First Alcohol Use Disorder Patients in CMND-100 Trial
CMND is trading near its 52-week low of $0.92 (9.8% above the low) on light trading volume (0.1× avg).
Summary
Clearmind has enrolled and dosed the first two patients with Alcohol Use Disorder in its Phase I/II trial of CMND-100 at Hadassah Medical Center. This is the first time the drug has been given to actual AUD patients, moving beyond healthy volunteer cohorts. The milestone follows the September 1 announcement that Phase IIa dosing had begun with six patients enrolled, and the September 8 Yale IRB approval for Parts B and C. For a micro-cap company with a going concern warning, this clinical progress is a meaningful step, though efficacy data remains far off. Next key readout will be safety and preliminary efficacy from these AUD patients, but no specific date has been provided.
At the time of this announcement, CMND was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.92 to $524.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.